Enanta Pharmaceuticals Inc (ENTA)
12.53
+0.05
(+0.40%)
USD |
NASDAQ |
Apr 26, 09:53
Enanta Pharmaceuticals Cash from Investing (TTM): -100.26M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -100.26M |
September 30, 2023 | -53.58M |
June 30, 2023 | -37.18M |
March 31, 2023 | 124.78M |
December 31, 2022 | 42.96M |
September 30, 2022 | 54.90M |
June 30, 2022 | 99.35M |
March 31, 2022 | 39.42M |
December 31, 2021 | 99.94M |
September 30, 2021 | 36.99M |
June 30, 2021 | -33.19M |
March 31, 2021 | 37.30M |
December 31, 2020 | 39.59M |
September 30, 2020 | 19.83M |
June 30, 2020 | -34.88M |
March 31, 2020 | -76.51M |
December 31, 2019 | -102.93M |
September 30, 2019 | -86.66M |
June 30, 2019 | -42.40M |
March 31, 2019 | -59.02M |
December 31, 2018 | -53.88M |
September 30, 2018 | -35.40M |
June 30, 2018 | -42.35M |
Date | Value |
---|---|
March 31, 2018 | -3.234M |
December 31, 2017 | -7.885M |
September 30, 2017 | -4.572M |
June 30, 2017 | 4.182M |
March 31, 2017 | -34.90M |
December 31, 2016 | -37.17M |
September 30, 2016 | -43.66M |
June 30, 2016 | -33.42M |
March 31, 2016 | 6.183M |
December 31, 2015 | -100.84M |
September 30, 2015 | -88.19M |
June 30, 2015 | -83.07M |
March 31, 2015 | -118.56M |
December 31, 2014 | 6.175M |
September 30, 2014 | 0.497M |
June 30, 2014 | -16.35M |
March 31, 2014 | -37.26M |
December 31, 2013 | -70.37M |
September 30, 2013 | -69.22M |
June 30, 2013 | -52.34M |
March 31, 2013 | -17.00M |
December 31, 2012 | -22.49M |
September 30, 2012 | -18.04M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-102.93M
Minimum
Dec 2019
124.78M
Maximum
Mar 2023
1.445M
Average
19.83M
Median
Sep 2020
Cash from Investing (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | -502.52M |
Galectin Therapeutics Inc | -- |
Viking Therapeutics Inc | -641.08M |
Akero Therapeutics Inc | -223.62M |
89bio Inc | -123.02M |